Partnership Spotlight: MET-TEST
See how we are utilizing MET-TEST's industry first standardized functional capacity assessment to improve provider insights into cardiovascular patients.MET-TEST & Prime ACO
Implementing the right therapy at the right time with physiology-guided care
MET-TEST is proud to be selected by Prime ACO to assist in taking outpatient cardiovascular disease (CVD) management to the next level. CVD is responsible for almost 2 out of every 3 dollars spent by Medicare on its beneficiaries. Making even small improvements in CV health will have a profound impact on the healthcare costs of any at-risk organization. MET-TEST and Prime-ACO are partnering to prolong the lifespan of each patient and to minimize the number of hospitalizations along the way. Enhanced outpatient management with continuous patient engagement and feedback are critical facets to improving long-term outcomes and decreasing costs.
MET-TEST is proud to be selected by Prime ACO to assist in taking outpatient cardiovascular disease (CVD) management to the next level. CVD is responsible for almost 2 out of every 3 dollars spent by Medicare on its beneficiaries. Making even small improvements in CV health will have a profound impact on the healthcare costs of any at-risk organization. MET-TEST and Prime-ACO are partnering to prolong the lifespan of each patient and to minimize the number of hospitalizations along the way. Enhanced outpatient management with continuous patient engagement and feedback are critical facets to improving long-term outcomes and decreasing costs.
It is recognized that 80% of CVD is preventable.
The key to improving the CV health of any population is to increase physical activity and to optimize medical therapy at the right-time, months and years before an event and not after. The common denominator in high cost patients is poor exercise or functional capacity which is precisely quantified by peak VO2. MET-TEST uses peak VO2 as a chronic cardiac vital sign that is one key component of risk-stratification of all individuals. Atherosclerotic heart disease will decrease peak VO2 and increase healthcare costs over time by causing cardiac dysfunction during exertion that occurs in all individuals that have an event (heart attack, stroke and heart failure).
It is recognized that 80% of CVD is preventable.
The key to improving the CV health of any population is to increase physical activity and to optimize medical therapy at the right-time, months and years before an event and not after. The common denominator in high cost patients is poor exercise or functional capacity which is precisely quantified by peak VO2. MET-TEST uses peak VO2 as a chronic cardiac vital sign that is one key component of risk-stratification of all individuals. Atherosclerotic heart disease will decrease peak VO2 and increase healthcare costs over time by causing cardiac dysfunction during exertion that occurs in all individuals that have an event (heart attack, stroke and heart failure).
MET-TEST specializes in identifying different patterns of cardiac dysfunction during exertion that few if any other entities are capable of detecting.
This expertise has developed over 12 years of working closely with doctors to manage patients with different levels of complexity in the primary care, cardiology and hospital settings. By implementing our proven guideline driven management algorithms in a systematic manner, the CV care of patients is standardized and key changes to lifestyle and medications are made earlier in the disease process. With serial testing, our reporting enables physicians to ensure patients are headed in the right direction –> increasing peak VO2 from baseline with reversal of underlying cardiac dysfunction. High peak VO2 patients also have the least cancer, kidney disease, dementia, osteoporosis and falls compared to low peak VO2 patients. This patient specific, customized approach avoids under and over-treatment with the goal to optimize outcomes.
This expertise has developed over 12 years of working closely with doctors to manage patients with different levels of complexity in the primary care, cardiology and hospital settings. By implementing our proven guideline driven management algorithms in a systematic manner, the CV care of patients is standardized and key changes to lifestyle and medications are made earlier in the disease process. With serial testing, our reporting enables physicians to ensure patients are headed in the right direction –> increasing peak VO2 from baseline with reversal of underlying cardiac dysfunction. High peak VO2 patients also have the least cancer, kidney disease, dementia, osteoporosis and falls compared to low peak VO2 patients. This patient specific, customized approach avoids under and over-treatment with the goal to optimize outcomes.
MET-TEST will work with Prime ACO to document the changes in physiological status of its population as the result of exercise and medical interventions, track the cost of care of these patients and report the findings in peer reviewed journals. We are excited to be engaging in this journey together and look forward to the challenges ahead!
MET-TEST will work with Prime ACO to document the changes in physiological status of its population as the result of exercise and medical interventions, track the cost of care of these patients and report the findings in peer reviewed journals. We are excited to be engaging in this journey together and look forward to the challenges ahead!